Press Releases

All Releases
View Summary Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Friday, November 10, 2017
PDF 11.8 KB Add to Briefcase
View Summary Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Thursday, November 9, 2017
PDF 103.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data
Tuesday, November 7, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Tuesday, November 7, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Announces Third Quarter 2017 Results and Provides Business Update
Monday, November 6, 2017
PDF 27.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Monday, October 30, 2017
PDF 13.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018
Monday, October 23, 2017
PDF 14.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6
Thursday, October 19, 2017
PDF 9.9 KB Add to Briefcase
View Summary Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Wednesday, October 18, 2017
PDF 12.0 KB Add to Briefcase
View Summary Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Wednesday, October 11, 2017
PDF 13.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Thursday, September 21, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 12.6 KB Add to Briefcase
View Summary Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 16.3 KB Add to Briefcase
View Summary Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Friday, September 1, 2017
PDF 14.9 KB Add to Briefcase
View Summary Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
Tuesday, August 29, 2017
PDF 11.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
Thursday, August 17, 2017
PDF 12.5 KB Add to Briefcase
View Summary Five Prime Announces Second Quarter 2017 Results and Provides Business Update
Tuesday, August 8, 2017
PDF 29.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8
Wednesday, July 26, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
Monday, July 17, 2017
PDF 13.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
Wednesday, June 21, 2017
PDF 13.4 KB Add to Briefcase
Showing 1-20 of 191 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
25.56
Change (%)
-0.20
Volume
409,193

Data as of 4:00 PM ET on Friday, November 17, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.